No Data
No Data
BMO Capital Maintains Centessa Pharmaceuticals(CNTA.US) With Buy Rating, Maintains Target Price $35
Jefferies Maintains Centessa Pharmaceuticals(CNTA.US) With Buy Rating, Raises Target Price to $27
Centessa Sleep Disorder Drug Sales Could Eventually Top $2.5B -- Market Talk
Centessa Pharmaceuticals' ORX750: Promising Phase I Results and Market Potential Justify Buy Rating
Centessa Pharmaceuticals: Promising OX2R Agonists for Unmet Narcolepsy Needs With Market Expansion Potential
Centessa Pharmaceuticals | 10-K: FY2024 Annual Report